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ABSTRACT Moxidectin is under consideration for development as a treatment for
human scabies. As some arthropods show decreased sensitivity to moxidectin rela-
tive to ivermectin, it was important to assess this for Sarcoptes scabiei. In vitro assays
showed that the concentration of moxidectin required to kill 50% of mites was
lower than that of ivermectin (0.5 M versus 1.8 M at 24 h; P  0.0001). This ﬁnd-
ing provides further support for moxidectin as a candidate for the treatment of hu-
man scabies.
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The macrocyclic lactones ivermectin and moxidectin have been widely utilized inveterinary practice for the treatment of Sarcoptes scabiei infestation. For human
scabies, ivermectin is the only licensed oral acaricide, with moxidectin under recent
consideration for development as an alternative to ivermectin (1). As moxidectin has a
prolonged plasma half-life (t1/2) in humans (29 to 47 days versus 14 h) (2–4), it is
anticipated that it may be more suitable than ivermectin as a single oral dose, providing
coverage over the entire mite life cycle.
Ivermectin is administered at a concentration of approximately 200 g/kg of body
weight for scabies, with rationale for this based on its activity against nematodes. There
have been no empirical dose-ﬁnding studies for scabies. It is acknowledged that doses
of 150 g/kg have reduced efﬁcacy (5–7), and it has been suggested that higher
doses may be advantageous (8). Suboptimal responses to ivermectin in some groups
(9–11) indicate that a more detailed investigation of optimal therapeutic doses in
scabies is warranted. This is particularly relevant with the utilization of ivermectin for
scabies mass treatment, where a single-dose regimen is desirable (12, 13). Moxidectin
has demonstrated activity against sarcoptic mange, although several studies suggest
that a single 200-g/kg dose is still insufﬁcient to achieve cure (14, 15), with long-acting
formulations or higher doses required (16). Other reports show 100% efﬁcacy following
a single 200- to 300-g/kg dose (17, 18).
Differences between ivermectin’s and moxidectin’s activities are apparent, especially
against arthropods (19–22). From this, questions emerge regarding the threshold for
acaricidal activity of both drugs over the mite life cycle and how this relates to
therapeutically relevant concentrations, bioavailability, and safety margins. In vitro
studies are a useful preclinical measure of relative toxicity and are routinely used to
measure acaricide’s activity against S. scabiei. In this study, we compared the in vitro
toxicities of ivermectin and moxidectin in S. scabiei var. suis.
Mites were harvested from pigs maintained at the Queensland Agricultural Science
Precinct (QASP), University of Queensland, Australia, with ethical approval from the
Queensland Department of Agriculture, Forestry, and Fisheries (approval SA 2015-03-
504). Scabies mites in this colony were originally obtained from naturally infested pigs
and have had no known acaricide exposure. Establishment of this model and protocols
Received 21 February 2017 Returned for
modiﬁcation 30 March 2017 Accepted 22
May 2017
Accepted manuscript posted online 30 May
2017
CitationMounsey KE, Walton SF, Innes A,
Cash-Deans S, Mccarthy JS. 2017. In vitro
efﬁcacy of moxidectin versus ivermectin
against Sarcoptes scabiei. Antimicrob Agents
Chemother 61:e00381-17. https://doi.org/10
.1128/AAC.00381-17.
Copyright © 2017 American Society for
Microbiology. All Rights Reserved.
Address correspondence to Kate E. Mounsey,
kmounsey@usc.edu.au.
SUSCEPTIBILITY
crossm
August 2017 Volume 61 Issue 8 e00381-17 aac.asm.org 1Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 10, 2018 by UQ Library
http://aac.asm
.org/
D
ow
nloaded from
 
for mite collection have been described in detail previously (23). Brieﬂy, skin scrapings
were obtained from the ears of infested pigs and transported to the laboratory. To
isolate mites, skin crusts were placed on glass petri dishes and incubated at 28°C, which
encourages mites to move out of the crusts toward the heat source.
In vitro assays were commenced within 4 h of collecting skin crusts. For all assays,
mortality was deﬁned as the absence of any movement when mites were gently
touched with a probe. We used injectable solutions of ivermectin (Ivomec; Merial) and
moxidectin (Cydectin; Virbac). An initial analysis was performed to compare the effects
of diluents on mite survival, using 10 adult female mites exposed to 50 M and 100 M
acaricides diluted in phosphate-buffered saline (PBS), mineral oil, or polyethylene glycol
(PEG). Negative controls (n  10) consisted of diluent in the absence of acaricide.
Mortality was measured at hourly intervals for up to 5 h and then again at 24 h.
Kaplan-Meier survival curves were generated, and the curves were compared statisti-
cally using the log rank (Mantel-Cox) test (GraphPad Prism 7). Results from these assays
were used to conﬁrm the most appropriate diluent for subsequent assays.
Next, assays to determine the concentration required to kill 50% of mites (50% lethal
concentration [LC50]) were conducted using female mites as previously described (24).
Stock solutions (200 M) and 2-fold serial dilutions (1.6 to 100 M) were prepared in
PBS immediately prior to use. Mortality was recorded at 1, 3, and 24 h postexposure.
Each compound was assayed in duplicate, with 10 mites per concentration, and assays
were repeated on three separate occasions (60 mites were tested at each concentra-
tion). LC50s were determined by normalized dose-response analysis and best-ﬁt curves
generated by nonlinear regression. The two regression models and LC50s were com-
pared statistically using the extra sum-of-squares F test (GraphPad Prism 7).
The LC50 assays were restricted to adult female mites to limit variation in suscepti-
bility due to differences in activities associated with developmental stages. To assess
this, we then compared the survival of adult females to that of juvenile and adult male
mites when exposed to a ﬁxed concentration of acaricide (6.5 M moxidectin or 12.5
M ivermectin) diluted in PBS. Fifteen mites per life stage were assessed in duplicate
assays (n  30).
These assays revealed that moxidectin was signiﬁcantly more active than ivermectin
at all time points tested (Fig. 1; Table 1). At 1 and 3 h postexposure, the reductions in
FIG 1 Dose-response curves of S. scabiei mortality after 1 h of in vitro exposure to serial dilutions of 0 to
200 M ivermectin and moxidectin. Points show median mortality; bars show standard errors. Sixty mites
per concentration were tested.
TABLE 1 Concentrations of ivermectin and moxidectin required to kill 50% of S. scabiei
mites at 1, 3, and 24 h postexposurea
Drug
1 h 3 h 24 h
LC50 (M) 95% CI LC50 (M) 95% CI LC50 (M) 95% CI
Ivermectin 50.5 45.4–56.4 10.5 8.2–13.5 1.8 1.18–2.68
Moxidectin 8.2b 7.6–8.9 1.4b 1.1–1.9 0.5b 0.34–0.77
aSixty mites per concentration were tested.
bP  0.0001.
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moxidectin’s micromolar LC50 relative to that of ivermectin were 6.2-fold and 7.5-fold,
respectively. LC50s decreased for both acaricides over time of exposure, and the
magnitude of difference in the LC50s of the drugs at 24 h was smaller (3.6-fold) but still
signiﬁcant (Table 1).
Survival analysis revealed signiﬁcant differences associated with developmental
stages. For ivermectin (12.5 M), median survival was 30 min for larvae, 1 h for nymphs
and adult males, and 2 h for adult females (Fig. 2A). For moxidectin (6.25 M), the
median survival time was 30 min for juvenile and male mites, compared to the 1 h for
females (Fig. 2B).
We also found that survival times of adult female mites exposed to 50 M ivermec-
tin were signiﬁcantly different depending on the diluent (1 to 2 h in PBS or PEG versus
4 h in mineral oil; P  0.0003). For 50 M moxidectin, no signiﬁcant differences
between diluents were apparent. Notably in all diluents, survival times with moxidectin
were signiﬁcantly reduced compared to those with ivermectin (P  0.0001). The
median survival time of negative controls for all assays exceeded 20 h, with no
statistical differences between diluents. These ﬁndings suggest that differences in
diluent should be considered when comparing data from other in vitro studies, at least
for ivermectin. Considering this, the median survival time for ivermectin in mineral oil
(1 h at 100 M) was consistent with previously reported in vitro data from S. scabiei var.
hominis mites prior to ivermectin exposure (for these S. scabiei var. hominis assays,
ointment containing 100 M ivermectin in parafﬁn oil was used). After 10 years of
ivermectin use, the median in vitro survival times with ivermectin doubled for these
mites (11). Precise LC50 estimates have not yet been undertaken in S. scabiei var.
hominis, nor has moxidectin been assessed in this population.
The in vitro LC50s reported here are in the range documented for other parasitic
arthropods and nematodes. The LC50 for ivermectin at 24 h (1.8 M) is similar to that
for a Cooperia sp. (1.7 M), Haemonchus contortus, and Strongyloides ratti (1.14 M)
(25–27), although in the last two nematodes, a high-throughput motility assay dem-
onstrated lower IC50s (0.34 M) (28). Where the ﬁlarial nematodes Brugia malayi and
Diroﬁlaria immitis are concerned, the ivermectin IC50s ranged from 4.6 to 28.2 M,
depending on life stage (27, 29). These concentrations are generally higher than have
been documented for arthropods for which ivermectin LC50s range from 23 nM (Cimex
FIG 2 In vitro survival of S. scabiei life stages upon exposure to 12.5 M ivermectin (A) or 6.25 M
moxidectin (B). Thirty mites at each life stage were tested.
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lectularius, Musca domestica, Anopheles gambiae) to 0.69 M (Aedes aegypti) (19, 20, 22).
There have been few studies on mites, although one recent report shows ivermectin’s
extremely high activity against spider mites (Tetranychus cinnabarinus; 10.3 nM) (30).
Variation in reported values are likely due to different assay methodologies, particularly
in arthropod assays which involve assessment of mortality after direct feeding (from a
spiked blood meal, for example), whereas our S. scabiei in vitro assays are primarily
contact based.
The ﬁnding that moxidectin was more toxic than ivermectin to S. scabiei is in
contrast to ﬁndings reported for other arthropods. The LC50 of moxidectin at 24 h for
A. gambiae (4.2 M) is over 100-fold higher than that of ivermectin (20). In spider mites,
ivermectin was 2-fold more active than milbemycin (30), although newly developed
synthetic milbemycins had higher activity (0.03 to 0.17 M) (31). Equivalent concen-
trations of moxidectin were less active than ivermectin against bed bugs (C. lectularius)
(22). Ivermectin was approximately 10 times more potent than moxidectin in a variety
of ﬂy species (19). Differences in toxicity between the macrocyclic lactones are less
apparent in nematodes (27); however, studies of B. malayi and Caenorhabditis elegans
show differences between phenotypic effects of the drugs, suggesting that different
target sites exist (32, 33). While moxidectin and ivermectin have similar mechanisms of
action, the existence of different binding targets is further reﬂected by differences in
ABC transporter-mediated efﬂux, for example (21). It is important to note that in other
parasites, considerable variation exists between in vitro susceptibility and plasma drug
concentrations, with the latter invariably lower (29). This is likely due to the aforemen-
tioned differences in modes of drug delivery (direct ingestion of skin and sera versus
absorption of the drug through the mite cuticle). Thus, while these in vitro studies are
a useful measure of relative toxicity which may aid clinical decision-making, the LC50s
cannot be directly transferred to the in vivo setting.
Notwithstanding the above, when considering the clinical relevance of these results,
how do these in vitro concentrations compare to bioavailability in skin? A recent study
of pig skin measured the maximum concentration (Cmax) of moxidectin in skin as 0.94
M and the t1/2 as 8.6 days, compared to only 0.069 M and 1 day for ivermectin (17).
While the moxidectin levels are within our in vitro susceptibility range, it is possible that
these levels of ivermectin might be insufﬁcient to kill all mites. In the above-described
study, ivermectin could not be detected in pig skin beyond 9 to 12 days posttreatment,
suggesting little activity against newly hatched eggs, although it is seen in our data that
juvenile mites are susceptible to lower drug concentrations. Our results explain in part
why single-dose moxidectin achieved 100% efﬁcacy in pigs at day 14, compared to
ivermectin’s 62% efﬁcacy (17). While moxidectin has excellent retention in the skin of
pigs and cattle (34), different pharmacokinetics may relate to observed differences in
treatment efﬁcacy in other species. There have been few reports regarding the skin
concentrations of ivermectin and moxidectin in humans. One study of ﬁve participants
measured an ivermectin Cmax of 0.023 M on the skin surface, with levels declining
after 24 h (35). Determination of the concentrations of moxidectin in human skin would
be of great beneﬁt, complementing the work herein and informing future dose-ﬁnding
studies.
This work contributes important preclinical data toward recently funded human
phase II efﬁcacy and dose-ﬁnding studies for moxidectin use in cases of scabies (36).
Our ﬁndings conﬁrm that S. scabiei is highly susceptible to moxidectin and that
moxidectin is superior to ivermectin in vitro. This increased susceptibility, combined
with enhanced bioavailability (4), provide strong support for the development of
moxidectin for human scabies.
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